OCUL | Ocular Therapeutix Inc
Category: Consumer goods
Quick infos Headquarters: Bedford, Massachusetts, United States Trade prices Volume: Market Cap: 313.95M Prev closed: Open: 4.92 High: 4.99 Low: 4.66 52 week low: 4.66 52 week high: 19.84 Dividends: No Dividends Next ER: May 8, 2023 After Market Closes
Earnings History Date EPS / Forecast Revenue / Forecast August 7, 2023 May 8, 2023 -0.39 / -0.2613.37M / 14.07MMarch 6, 2023 -0.24 / -0.2514.1M / 13.42MBeat! November 7, 2022 -0.31 / -0.238311.97M / 14.27MAugust 8, 2022 -0.25 / -0.22212.27M / 14.25Mview more
Historical Data Date Price Open High Low Vol Change ER Jun 15, 2023 4.97 5.28 5.35
4.94
2.4M -6.4% Jun 14, 2023 5.31 6.35 6.4
5.18
5.4M -16.38% Jun 13, 2023 6.35 6.61 6.7
6.21
2.9M -2.31% Jun 12, 2023 6.5 7.44 7.96
6.34
4.9M -12.52% Jun 9, 2023 7.43 7.65 7.71
7.34
782K -2.37% Jun 8, 2023 7.61 7.36 7.7
7.09
1.2M 2.70% Jun 7, 2023 7.41 7.67 7.74
7.38
1.5M -3.01% Jun 6, 2023 7.64 7.25 7.67
7.19
1.5M 5.67% Jun 5, 2023 7.23 6.93 7.3
6.88
933K 4.48% Jun 2, 2023 6.92 6.49 6.93
6.32
1.1M 7.79% view more
NASDAQ - Nasdaq Stock Market
News
Ocular Therapeutix Reports Third Quarter 2022 Financial Results and Business Update finance.yahoo.com Jun 16, 2023 4:01 pm
Ocular Therapeutix Provides First Quarter 2023 Financial Results and Corporate Update finance.yahoo.com Jun 16, 2023 4:01 pm
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2022 Earnings Call Transcript finance.yahoo.com Jun 16, 2023 7:21 am
Q1 2023 Ocular Therapeutix Inc Earnings Call finance.yahoo.com Jun 16, 2023 6:21 am
Ocular Therapeutix Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD finance.yahoo.com Jun 10, 2023 6:30 pm
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is definitely on the radar of institutional investors who own 45% of the company finance.yahoo.com Jun 2, 2023 9:37 am
Ocular Therapeutix To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting finance.yahoo.com Apr 28, 2023 8:00 am
Ocular Therapeutix (NASDAQ:OCUL) shareholders have endured a 21% loss from investing in the stock five years ago finance.yahoo.com Apr 7, 2023 8:49 am Ocular Therapeutix stock rises after posting Q4 results beat, strong guidance seekingalpha.com Mar 8, 2023 4:39 am Ocular Therapeutix Q4 GAAP EPS, revenue beats, guidance below consensus seekingalpha.com Mar 7, 2023 5:04 am
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates finance.yahoo.com Mar 6, 2023 5:15 pm Ocular Therapeutix Q4 2022 Earnings Preview seekingalpha.com Mar 6, 2023 6:35 am
Chinook Therapeutics (KDNY) Reports Q4 Loss, Tops Revenue Estimates finance.yahoo.com Feb 27, 2023 5:15 pm
Ocular Therapeutix Shares Jump On Favorable Data From Intravitreal Implant Study In Wet AMD finance.yahoo.com Feb 13, 2023 5:52 am
With 48% stake, Ocular Therapeutix, Inc. (NASDAQ:OCUL) seems to have captured institutional investors' interest finance.yahoo.com Dec 24, 2022 7:34 am
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised) finance.yahoo.com Dec 7, 2022 5:25 pm
Ocular Therapeutix Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD finance.yahoo.com Dec 7, 2022 6:00 am
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised) finance.yahoo.com Dec 7, 2022 5:38 am Ocular stock rises ~15% as eye drug implant shows promise in ongoing phase 1 trial seekingalpha.com Feb 13, 2023 6:05 pm
These Analysts Just Made A Neat Downgrade To Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Forecasts finance.yahoo.com Nov 13, 2022 7:10 am This company doesn't provide a dividend.
Talk about Ocular Therapeutix Inc below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus BUY 100 HOLD 0 SELL 0
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.